Research & Development

Haplogen, Bayer enter into drug discovery and development collaboration

Haplogen and German pharma firm Bayer have entered into a collaboration to develop drug candidates for the treatment of chronic obstructive pulmonary disease (COPD) and other pulmonary diseases.

Orchard Therapeutics raises $150m to advance gene therapies for rare diseases

Orchard Therapeutics, a biotechnology company focused on developing gene therapies for rare diseases, has raised $150m through a Series C funding round.

Aralez Pharmaceuticals agrees to sell main operating businesses

Canadian specialty pharmaceutical firm Aralez Pharmaceuticals has entered into two separate agreements to sell substantially all of its assets for a total of $250m.

Therachon raises $60m to expand rare disease pipeline

Clinical-stage biotechnology firm Therachon has raised $60m mezzanine financing to advance lead program in achondroplasia and expand rare disease pipeline.

OvaScience, Millendo Therapeutics agree to merge

Biotechnology ccompany OvaScience and clinical-stage biopharmaceutical firm Millendo Therapeutics have signed a merger agreement to create a rare endocrine disease company.

Scancell expands Moditope collaboration with Karolinska Institute

Scancell Holdings, a developer of immunotherapies to treat cancer, has expanded its research collaboration with the rheumatology unit at the Karolinska Institute Sweden.

Takeda collaborates with Ambys on liver disease therapies

Japanese drugmaker Takeda has partnered with biotechnology firm Ambys Medicines to pioneer therapies for the treatment of serious liver diseases.

Apexigen raises $73m to advance immuno-oncology product development

Apexigen, a clinical-stage biopharmaceutical company engaged in the discovery and development of a new generation of antibody therapeutics for oncology, has raised $73m in Series B And Series C financings.

Teneobio, Poseida extend collaboration to develop UniDabs for advanced CAR-T therapies

Teneobio and Poseida Therapeutics have entered into a new research collaboration and licensing agreement to develop novel CAR-T therapies using Teneobio’s heavy chain only domain antibodies (UniDabs).